ReviewCell stress2019
Biology and clinical relevance of EpCAM.
Review in Cell stress, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 193 citations in OpenAlex.
- Clinicopathologic relevance of EpCAM and CD44 in pancreatic cancer: insights from a meta-analysis.Stem cell research & therapy · 2025Pooled it
- Epigenetic inactivation of ACAT1 promotes epithelial-mesenchymal transition of clear cell renal cell carcinoma.Genes & genomics · 2022Pooled it
- The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation.Biomarker research · 2026Review
- Spatial transcriptomics reveals immune remodeling in lymph nodes of gastric adenocarcinoma.Clinical & experimental metastasis · 2026Article
- Integrated RNA Sequencing and Multi-Bioinformatics Analyses Reveal the Molecular Mechanisms Underlying the Anti-Breast Cancer Effects of the Fritillariae Thunbergii Bulbus-Bolbostemmatis Rhizoma Herb Pair.Cell biochemistry and function · 2026Article
- Intrinsic cellular heterogeneity directs divergent epithelial-to-mesenchymal transition outcomes.The FEBS journal · 2026Article
- Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.Molecular oncology · 2026Article
- Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC.BMC cancer · 2026Article
- Article
- Uncovering potentially targetable genes in liver fibrosis via bioinformatics and experimental validation.Scientific reports · 2026Article
- Implication of Epigenetic Alterations of ZEB1 in Colorectal Cancer (CRC) Pathogenesis and Therapy Development.Current issues in molecular biology · 2026Review
- Circulating tumor cells (CTCs) enumeration and machine-learning based diagnostic biomarkers for breast cancer detection.BMC cancer · 2026Article
- Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins.Discover oncology · 2026Review
- Single nuclei and spatial profiling of sacrococcygeal teratomas reveals cellular composition and X inactivation heterogeneity.NPJ precision oncology · 2026Article
- MagSculptor: A Microfluidic Platform for High-Resolution Magnetic Fractionation of Low-Expression Cell Subtypes.Biosensors · 2026Article
- Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels.BioMed research international · 2026Article
- Genotype-phenotype correlations inFrontiers in pediatrics · 2026Article
- High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?Journal for immunotherapy of cancer · 2025Review
- The clinical value of the EpCAM biomarker and its association with immune cell infiltration in bladder cancer.Diagnostic pathology · 2025Article
- Nanovaccine targeting in colorectal cancer: a multi-dataset analysis of CEA expression, cytokine profiles, and co-expressed genes.Medicine and pharmacy reports · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein primarily known to mediate homotypic cell contacts in epithelia tissues. Because EpCAM expression is limited to normal and malignant epithelia, it has been used as diagnostic marker for the detection of carcinoma cells in mesenchymal organs such as blood, bone marrow or lymph nodes. In particular, the detection and molecular characterization of EpCAM-positive circulating tumor cells (CTCs) in the blood of carcinoma patients has gained considerable interest over the past ten years. EpCAM is primarily considered as an adhesion molecule, but recent studies have shown diverse biological functions including regulation of cell proliferation and cancer stemness. In this review, we summarize the current knowledge on the biological properties of EpCAM with emphasis on mechanisms involved in cancer progression and discuss the clinical implications of these findings for the clinical use of EpCAM as a diagnostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.